Pink SheetTo avoid public disagreement, US Food and Drug Administration center directors should spend more time with their staff earlier in a product’s review, outgoing Commissioner Robert Califf said. Public d
ScripLilly Misses 2024 Guidance, Expects More In 2025 Eli Lilly pre-announced its full-year 2024 revenue, which missed analyst consensus and the company’s own guidance, and provided its 2025 revenue guidan
ScripSarepta Therapeutics CEO Doug Ingram has been reflecting on “the most significant year to date” for the company at the J.P. Morgan Healthcare Conference in San Francisco and trumpeted the “exceptional
Pink SheetSeven new advanced therapy medicinal products (ATMPs) could be approved for pan-EU approval this year, based on data from the Pink Sheet’s EU regulatory filings tracker , including Roche / Sarepta